Mild behavioral impairment in early Alzheimer's disease and its association with APOE and BDNF risk genetic polymorphisms.
Alzheimer’s disease
Mild behavioral impairment
Mild cognitive impairment
Neuropsychiatric symptoms
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
26 Jan 2024
26 Jan 2024
Historique:
received:
13
04
2023
accepted:
04
01
2024
medline:
27
1
2024
pubmed:
27
1
2024
entrez:
26
1
2024
Statut:
epublish
Résumé
Mild behavioral impairment (MBI) has been commonly reported in early Alzheimer's disease (AD) but rarely using biomarker-defined samples. It is also unclear whether genetic polymorphisms influence MBI in such individuals. We thus aimed to examine the association between the cognitive status of participants (amnestic mild cognitive impairment (aMCI-AD) vs cognitively normal (CN) older adults) and MBI severity. Within aMCI-AD, we further examined the association between APOE and BDNF risk genetic polymorphisms and MBI severity. We included 62 aMCI-AD participants and 50 CN older adults from the Czech Brain Aging Study. The participants underwent neurological, comprehensive neuropsychological examination, APOE and BDNF genotyping, and magnetic resonance imaging. MBI was diagnosed with the Mild Behavioral Impairment Checklist (MBI-C), and the diagnosis was based on the MBI-C total score ≥ 7. Additionally, self-report instruments for anxiety (the Beck Anxiety Inventory) and depressive symptoms (the Geriatric Depression Scale-15) were administered. The participants were stratified based on the presence of at least one risk allele in genes for APOE (i.e., e4 carriers and non-carriers) and BDNF (i.e., Met carriers and non-carriers). We used linear regressions to examine the associations. MBI was present in 48.4% of the aMCI-AD individuals. Compared to the CN, aMCI-AD was associated with more affective, apathy, and impulse dyscontrol but not social inappropriateness or psychotic symptoms. Furthermore, aMCI-AD was related to more depressive but not anxiety symptoms on self-report measures. Within the aMCI-AD, there were no associations between APOE e4 and BDNF Met and MBI-C severity. However, a positive association between Met carriership and self-reported anxiety appeared. MBI is frequent in aMCI-AD and related to more severe affective, apathy, and impulse dyscontrol symptoms. APOE and BDNF polymorphisms were not associated with MBI severity separately; however, their combined effect warrants further investigation.
Sections du résumé
BACKGROUND
BACKGROUND
Mild behavioral impairment (MBI) has been commonly reported in early Alzheimer's disease (AD) but rarely using biomarker-defined samples. It is also unclear whether genetic polymorphisms influence MBI in such individuals. We thus aimed to examine the association between the cognitive status of participants (amnestic mild cognitive impairment (aMCI-AD) vs cognitively normal (CN) older adults) and MBI severity. Within aMCI-AD, we further examined the association between APOE and BDNF risk genetic polymorphisms and MBI severity.
METHODS
METHODS
We included 62 aMCI-AD participants and 50 CN older adults from the Czech Brain Aging Study. The participants underwent neurological, comprehensive neuropsychological examination, APOE and BDNF genotyping, and magnetic resonance imaging. MBI was diagnosed with the Mild Behavioral Impairment Checklist (MBI-C), and the diagnosis was based on the MBI-C total score ≥ 7. Additionally, self-report instruments for anxiety (the Beck Anxiety Inventory) and depressive symptoms (the Geriatric Depression Scale-15) were administered. The participants were stratified based on the presence of at least one risk allele in genes for APOE (i.e., e4 carriers and non-carriers) and BDNF (i.e., Met carriers and non-carriers). We used linear regressions to examine the associations.
RESULTS
RESULTS
MBI was present in 48.4% of the aMCI-AD individuals. Compared to the CN, aMCI-AD was associated with more affective, apathy, and impulse dyscontrol but not social inappropriateness or psychotic symptoms. Furthermore, aMCI-AD was related to more depressive but not anxiety symptoms on self-report measures. Within the aMCI-AD, there were no associations between APOE e4 and BDNF Met and MBI-C severity. However, a positive association between Met carriership and self-reported anxiety appeared.
CONCLUSIONS
CONCLUSIONS
MBI is frequent in aMCI-AD and related to more severe affective, apathy, and impulse dyscontrol symptoms. APOE and BDNF polymorphisms were not associated with MBI severity separately; however, their combined effect warrants further investigation.
Identifiants
pubmed: 38279143
doi: 10.1186/s13195-024-01386-y
pii: 10.1186/s13195-024-01386-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21Subventions
Organisme : NIMH NIH HHS
ID : T32MH019934
Pays : United States
Organisme : CIHR
ID : BCA 2633
Pays : Canada
Informations de copyright
© 2024. The Author(s).
Références
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.
pubmed: 21514250
pmcid: 3312024
doi: 10.1016/j.jalz.2011.03.005
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9.
pubmed: 21514249
pmcid: 3312027
doi: 10.1016/j.jalz.2011.03.008
Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.
pubmed: 29653606
pmcid: 5958625
doi: 10.1016/j.jalz.2018.02.018
Wise EA, Rosenberg PB, Lyketsos CG, Leoutsakos JM. Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer’s Coordinating Centers volunteers. Alzheimers Dement (Amst). 2019;18(11):333–9.
doi: 10.1016/j.dadm.2019.02.006
Roberto N, Portella MJ, Marquié M, Alegret M, Hernández I, Mauleón A, et al. Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis. Sci Rep. 2021;11(1):6448.
pubmed: 33742011
pmcid: 7979780
doi: 10.1038/s41598-021-83126-y
Paradise M, McCade D, Hickie IB, Diamond K, Lewis SJG, Naismith SL. Caregiver burden in mild cognitive impairment. Aging Ment Health. 2015;19(1):72–8.
pubmed: 24866046
doi: 10.1080/13607863.2014.915922
Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12(2):195–202.
pubmed: 26096665
doi: 10.1016/j.jalz.2015.05.017
Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, et al. The Mild Behavioral Impairment Checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations. J Alzheimers Dis. 2017;56(3):929–38.
pubmed: 28059789
pmcid: 5652315
doi: 10.3233/JAD-160979
Hu S, Patten S, Charlton A, Fischer K, Fick G, Smith EE, et al. Validating the mild behavioral impairment checklist in a cognitive clinic: comparisons with the Neuropsychiatric Inventory Questionnaire. J Geriatr Psychiatry Neurol. 2022;17:08919887221093353.
Mallo SC, Ismail Z, Pereiro AX, Facal D, Lojo-Seoane C, Campos-Magdaleno M, et al. Assessing mild behavioral impairment with the Mild Behavioral Impairment-Checklist in people with mild cognitive impairment. J Alzheimers Dis. 2018;66(1):83–95.
pubmed: 30175974
doi: 10.3233/JAD-180131
Mallo SC, Ismail Z, Pereiro AX, Facal D, Lojo-Seoane C, Campos-Magdaleno M, et al. Assessing mild behavioral impairment with the mild behavioral impairment checklist in people with subjective cognitive decline. Int Psychogeriatr. 2018;18:1–9.
Eikelboom WS, van den Berg E, Singleton EH, Baart SJ, Coesmans M, Leeuwis AE, et al. Neuropsychiatric and cognitive symptoms across the Alzheimer disease clinical spectrum: cross-sectional and longitudinal associations. Neurology. 2021;97(13):e1276–87.
pubmed: 34413181
pmcid: 8480405
doi: 10.1212/WNL.0000000000012598
Wang Y, Lou F, Li Y, Liu F, Wang Y, Cai L, et al. Clinical, neuropsychological, and neuroimaging characteristics of amyloid-positive vs. amyloid-negative patients with clinically diagnosed Alzheimer’s disease and amnestic mild cognitive impairment. Curr Alzheimer Res. 2021;18(6):523–32.
pubmed: 34598664
doi: 10.2174/1567205018666211001113349
Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10-16.
pubmed: 9153155
Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol. 1986;5(1–2):165–73.
Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893–7.
pubmed: 3204199
doi: 10.1037/0022-006X.56.6.893
Banning LCP, Ramakers IHGB, Deckers K, Verhey FRJ, Aalten P. Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer’s disease: a systematic literature review. Neurosci Biobehav Rev. 2019;1(107):346–59.
doi: 10.1016/j.neubiorev.2019.09.014
Ng KP, Chiew H, Rosa-Neto P, Kandiah N, Ismail Z, Gauthier S. Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals. Transl Neurodegener. 2021;10(1):11.
pubmed: 33789730
pmcid: 8011383
doi: 10.1186/s40035-021-00236-3
Mortby ME, Ismail Z, Anstey KJ. Prevalence estimates of mild behavioral impairment in a population-based sample of pre-dementia states and cognitively healthy older adults. Int Psychogeriatr. 2018;30(2):221–32.
pubmed: 28931446
doi: 10.1017/S1041610217001909
Sheikh F, Ismail Z, Mortby ME, Barber P, Cieslak A, Fischer K, et al. Prevalence of mild behavioral impairment in mild cognitive impairment and subjective cognitive decline, and its association with caregiver burden. Int Psychogeriatr. 2018;30(2):233–44.
pubmed: 28879833
doi: 10.1017/S104161021700151X
Creese B, Ismail Z. Mild behavioral impairment: measurement and clinical correlates of a novel marker of preclinical Alzheimer’s disease. Alzheimers Res Ther. 2022;14(1):2.
pubmed: 34986891
pmcid: 8734161
doi: 10.1186/s13195-021-00949-7
Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, et al. Neuropsychiatric symptoms in Alzheimer’s disease: past progress and anticipation of the future. Alzheimers Dement. 2013;9(5):602–8.
pubmed: 23562430
pmcid: 3766403
doi: 10.1016/j.jalz.2012.12.001
Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–18.
pubmed: 23296339
pmcid: 3726719
doi: 10.1038/nrneurol.2012.263
Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med. 1996;47:387–400.
pubmed: 8712790
doi: 10.1146/annurev.med.47.1.387
Joie RL, Visani AV, Lesman-Segev OH, Baker SL, Edwards L, Iaccarino L, et al. Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET. Neurology. 2021;96(5):e650–61.
pubmed: 33262228
pmcid: 7884991
Scheltens NME, Tijms BM, Koene T, Barkhof F, Teunissen CE, Wolfsgruber S, et al. Cognitive subtypes of probable Alzheimer’s disease robustly identified in four cohorts. Alzheimers Dement. 2017;13(11):1226–36.
pubmed: 28427934
pmcid: 5857387
doi: 10.1016/j.jalz.2017.03.002
Weintraub S, Teylan M, Rader B, Chan KCG, Bollenbeck M, Kukull WA, et al. APOE is a correlate of phenotypic heterogeneity in Alzheimer disease in a national cohort. Neurology. 2020;94(6):e607–12.
pubmed: 31704790
pmcid: 7136069
doi: 10.1212/WNL.0000000000008666
Borroni B, Costanzi C, Padovani A. Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease. Curr Alzheimer Res. 2010;7(2):158–64.
pubmed: 19715553
doi: 10.2174/156720510790691173
Panza F, Frisardi V, Seripa D, D’Onofrio G, Santamato A, Masullo C, et al. Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer’s disease. Ageing Res Rev. 2012;11(1):87–103.
pubmed: 21763789
doi: 10.1016/j.arr.2011.06.005
Tsang RSM, Mather KA, Sachdev PS, Reppermund S. Systematic review and meta-analysis of genetic studies of late-life depression. Neurosci Biobehav Rev. 2017;75:129–39.
pubmed: 28137459
doi: 10.1016/j.neubiorev.2017.01.028
Banning LCP, Ramakers IHGB, Deckers K, Verhey FRJ, Aalten P. Apolipoprotein E and affective symptoms in mild cognitive impairment and Alzheimer’s disease dementia: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2019;1(96):302–15.
doi: 10.1016/j.neubiorev.2018.11.020
Holmes SE, Esterlis I, Mazure CM, Lim YY, Ames D, Rainey-Smith S, et al. β-Amyloid, APOE and BDNF genotype, and depressive and anxiety symptoms in cognitively normal older women and men. Am J Geriatr Psychiatry. 2016;24(12):1191–5.
pubmed: 27742526
doi: 10.1016/j.jagp.2016.08.007
Andrews SJ, Ismail Z, Anstey KJ, Mortby M. Association of Alzheimer’s genetic loci with mild behavioral impairment. Am J Med Genet B Neuropsychiatr Genet. 2018;177(8):727–35.
pubmed: 30378268
doi: 10.1002/ajmg.b.32684
Vellone D, Ghahremani M, Goodarzi Z, Forkert ND, Smith EE, Ismail Z. Apathy and APOE in mild behavioral impairment, and risk for incident dementia. Alzheimers Dement (N Y). 2022;8(1):e12370.
pubmed: 36544988
doi: 10.1002/trc2.12370
Brown DT, Vickers JC, Stuart KE, Cechova K, Ward DD. The BDNF Val66Met polymorphism modulates resilience of neurological functioning to brain ageing and dementia: a narrative review. Brain Sci. 2020;10(4):195.
pubmed: 32218234
pmcid: 7226504
doi: 10.3390/brainsci10040195
Pei Y, Smith AK, Wang Y, Pan Y, Yang J, Chen Q, et al. The brain-derived neurotrophic-factor (BDNF) val66met polymorphism is associated with geriatric depression: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2012;159B(5):560–6.
pubmed: 22610920
pmcid: 3549636
doi: 10.1002/ajmg.b.32062
Singh-Manoux A, Dugravot A, Fournier A, Abell J, Ebmeier K, Kivimäki M, et al. Trajectories of depressive symptoms before diagnosis of dementia. JAMA Psychiat. 2017;74(7):712–8.
doi: 10.1001/jamapsychiatry.2017.0660
Steenland K, Karnes C, Seals R, Carnevale C, Hermida A, Levey A. Late-life depression as a risk factor for mild cognitive impairment or Alzheimer’s disease in 30 US Alzheimer’s disease centers. J Alzheimers Dis. 2012;31(2):265–75.
pubmed: 22543846
pmcid: 3729228
doi: 10.3233/JAD-2012-111922
Tapiainen V, Hartikainen S, Taipale H, Tiihonen J, Tolppanen AM. Hospital-treated mental and behavioral disorders and risk of Alzheimer’s disease: a nationwide nested case-control study. Eur Psychiatry. 2017;43:92–8.
pubmed: 28388490
doi: 10.1016/j.eurpsy.2017.02.486
Borroni B, Archetti S, Costanzi C, Grassi M, Ferrari M, Radeghieri A, et al. Role of BDNF Val66Met functional polymorphism in Alzheimer’s disease-related depression. Neurobiol Aging. 2009;30(9):1406–12.
pubmed: 18179845
doi: 10.1016/j.neurobiolaging.2007.11.023
Zhang L, Fang Y, Zeng Z, Lian Y, Wei J, Zhu H, et al. BDNF gene polymorphisms are associated with Alzheimer’s disease-related depression and antidepressant response. J Alzheimers Dis. 2011;26(3):523–30.
pubmed: 21677379
doi: 10.3233/JAD-2011-110113
Holmes SE, Esterlis I, Mazure CM, Lim YY, Ames D, Rainey-Smith S, et al. Trajectories of depressive and anxiety symptoms in older adults: a 6-year prospective cohort study. Int J Geriatr Psychiatry. 2018;33(2):405–13.
pubmed: 28736899
doi: 10.1002/gps.4761
Nagata T, Kobayashi N, Shinagawa S, Yamada H, Kondo K, Nakayama K. Plasma BDNF levels are correlated with aggressiveness in patients with amnestic mild cognitive impairment or Alzheimer disease. J Neural Transm. 2014;121(4):433–41.
pubmed: 24253237
doi: 10.1007/s00702-013-1121-y
Cechova K, Andel R, Angelucci F, Chmatalova Z, Markova H, Laczó J, et al. Impact of APOE and BDNF Val66Met gene polymorphisms on cognitive functions in patients with amnestic mild cognitive impairment. J Alzheimers Dis. 2020;73(1):247–57.
pubmed: 31771052
doi: 10.3233/JAD-190464
Laczó J, Cechova K, Parizkova M, Lerch O, Andel R, Matoska V, et al. The combined effect of APOE and BDNF Val66Met polymorphisms on spatial navigation in older adults. J Alzheimers Dis. 2020;78(4):1473–92.
pubmed: 33325388
pmcid: 7836052
doi: 10.3233/JAD-200615
Matuskova V, Ismail Z, Nikolai T, Markova H, Cechova K, Nedelska Z, et al. Mild behavioral impairment is associated with atrophy of entorhinal cortex and hippocampus in a memory clinic cohort. Front Aging Neurosci. 2021;24(13):643271.
doi: 10.3389/fnagi.2021.643271
Sheardova K, Vyhnalek M, Nedelska Z, Laczo J, Andel R, Marciniak R, et al. Czech Brain Aging Study (CBAS): prospective multicentre cohort study on risk and protective factors for dementia in the Czech Republic. BMJ Open. 2019;9(12):e030379.
pubmed: 31857299
pmcid: 6937049
doi: 10.1136/bmjopen-2019-030379
Nikolai T, Stepankova H, Kopecek M, Sulc Z, Vyhnalek M, Bezdicek O. The uniform data set, Czech version: normative data in older adults from an international perspective. J Alzheimers Dis. 2018;61(3):1233–40.
pubmed: 29332045
pmcid: 6939612
doi: 10.3233/JAD-170595
Nikolai T, Štěpánková H, Michalec J, Bezdíček O, Horáková K, Marková H, et al. Verbal Fluency Tests – Czech normative study for older persons. Cesk Slov Neurol N. 2015;78(111):292–9.
doi: 10.14735/amcsnn2015292
Drozdová K, Štěpánková H, Lukavský J, Bezdíček O, Kopeček M. Normative data for the Rey- Osterrieth Complex Figure Test in older Czech adults. Cesk Slov Neurol N. 2015;78(111):542–9.
Bezdicek O, Lukavsky J, Stepankova H, Nikolai T, Axelrod BN, Michalec J, et al. The Prague Stroop Test: normative standards in older Czech adults and discriminative validity for mild cognitive impairment in Parkinson’s disease. J Clin Exp Neuropsychol. 2015;37(8):794–807.
pubmed: 26313510
doi: 10.1080/13803395.2015.1057106
Matuskova V, Nikolai T, Markova H, Cechova K, Laczo J, Hort J, et al. Neuropsychiatrické symptomy jako časná manifestace Alzheimerovy nemoci. Cesk Slov Neurol N. 2020;83(1):64–72.
Kassam F, Chen H, Nosheny RL, McGirr A, Williams T, Ng N, et al. Cognitive profile of people with mild behavioral impairment in Brain Health Registry participants. Int Psychogeriatr. 2022;8:1–10.
Ghahremani M, Nathan S, Smith EE, McGirr A, Goodyear B, Ismail Z. Functional connectivity and mild behavioral impairment in dementia-free elderly. Alzheimers Dement. 2023;9(1):e12371.
doi: 10.1002/trc2.12371
Creese B, Arathimos R, Brooker H, Aarsland D, Corbett A, Lewis C, et al. Genetic risk for Alzheimer’s disease, cognition, and mild behavioral impairment in healthy older adults. Alzheimers Dement. 2021;13(1):e12164.
Gitlin LN, Marx KA, Stanley IH, Hansen BR, Van Haitsma KS. Assessing neuropsychiatric symptoms in people with dementia: a systematic review of measures. Int Psychogeriatr. 2014;26(11):1805–48.
pubmed: 25096416
pmcid: 4435793
doi: 10.1017/S1041610214001537
Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31(3):545–8.
pubmed: 2341813
doi: 10.1016/S0022-2275(20)43176-1
Laczó J, Andel R, Vlček K, Macoška V, Vyhnálek M, Tolar M, et al. Spatial navigation and APOE in amnestic mild cognitive impairment. Neurodegener Dis. 2011;8(4):169–77.
pubmed: 21124005
doi: 10.1159/000321581
Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement. 2012;8(1):65–73.
pubmed: 22047631
doi: 10.1016/j.jalz.2011.07.004
Belohlavek O, Jaruskova M, Skopalova M, Szarazova G, Simonova K. Improved beta-amyloid PET reproducibility using two-phase acquisition and grey matter delineation. Eur J Nucl Med Mol Imaging. 2019;46(2):297–303.
pubmed: 30159586
doi: 10.1007/s00259-018-4140-y
Ghahremani M, Wang M, Chen HY, Zetterberg H, Smith E, Ismail Z, et al. Plasma phosphorylated tau at threonine 181 and neuropsychiatric symptoms in preclinical and prodromal Alzheimer disease. Neurology. 2023;100(7):e683–93.
pubmed: 36323521
pmcid: 9969916
doi: 10.1212/WNL.0000000000201517
Lussier FZ, Pascoal TA, Chamoun M, Therriault J, Tissot C, Savard M, et al. Mild behavioral impairment is associated with β-amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. Alzheimers Dement. 2020;16(1):192–9.
pubmed: 31914223
pmcid: 7041633
doi: 10.1002/alz.12007
Johansson M, Stomrud E, Insel PS, Leuzy A, Johansson PM, Smith R, et al. Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s disease. Transl Psychiatry. 2021;11(1):76.
pubmed: 33500386
pmcid: 7838407
doi: 10.1038/s41398-021-01206-z
Kianimehr G, Fatehi F, Noroozian M. Prevalence of mild behavioral impairment in patients with mild cognitive impairment. Acta Neurol Belg. 2022;122:1493–7. https://doi.org/10.1007/s13760-021-01724-z .
Pan Y, Shea YF, Li S, Chen R, Mak HKF, Chiu PKC, et al. Prevalence of mild behavioural impairment: a systematic review and meta-analysis. Psychogeriatrics. 2021;21(1):100–11.
pubmed: 33260271
doi: 10.1111/psyg.12636
Geda YE, Roberts RO, Knopman DS, Petersen RC, Christianson TJH, Pankratz VS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry. 2008;65(10):1193–8.
pubmed: 18838636
pmcid: 2575648
doi: 10.1001/archpsyc.65.10.1193
Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry. 2013;21(7):685–95.
pubmed: 23567400
doi: 10.1016/j.jagp.2013.01.006
Sugarman MA, Alosco ML, Tripodis Y, Steinberg EG, Stern RA. Neuropsychiatric symptoms and the diagnostic stability of mild cognitive impairment. J Alzheimers Dis. 2018;62(4):1841–55.
pubmed: 29614641
pmcid: 6548196
doi: 10.3233/JAD-170527
Desmarais P, Lanctôt KL, Masellis M, Black SE, Herrmann N. Social inappropriateness in neurodegenerative disorders. Int Psychogeriatr. 2018;30(2):197–207.
pubmed: 28689508
doi: 10.1017/S1041610217001260
Fischer CE, Agüera-Ortiz L. Psychosis and dementia: risk factor, prodrome, or cause? Int Psychogeriatr. 2018;30(2):209–19.
pubmed: 28560931
doi: 10.1017/S1041610217000874
Ismail Z, Creese B, Aarsland D, Kales HC, Lyketsos CG, Sweet RA, et al. Psychosis in Alzheimer disease—mechanisms, genetics and therapeutic opportunities. Nat Rev Neurol. 2022;18(3):131–44.
pubmed: 34983978
pmcid: 9074132
doi: 10.1038/s41582-021-00597-3
Dietlin S, Soto M, Kiyasova V, Pueyo M, de Mauleon A, Delrieu J, et al. Neuropsychiatric symptoms and risk of progression to Alzheimer’s disease among mild cognitive impairment subjects. J Alzheimers Dis. 2019;70(1):25–34.
pubmed: 31127783
doi: 10.3233/JAD-190025
Ismail Z, Elbayoumi H, Fischer CE, Hogan DB, Millikin CP, Schweizer T, et al. Prevalence of depression in patients with mild cognitive impairment: a systematic review and meta-analysis. JAMA Psychiat. 2017;74(1):58–67.
doi: 10.1001/jamapsychiatry.2016.3162
Masters MC, Morris JC, Roe CM. “Noncognitive” symptoms of early Alzheimer disease. Neurology. 2015;84(6):617–22.
pubmed: 25589671
pmcid: 4335988
doi: 10.1212/WNL.0000000000001238
Slifer MA, Martin ER, Gilbert JR, Haines JL, Pericak-Vance MA. Resolving the relationship between apolipoprotein E and depression. Neurosci Lett. 2009;455(2):116–9.
pubmed: 19368858
pmcid: 2945257
doi: 10.1016/j.neulet.2009.03.007
Dissanayake AS, Tan YB, Bowie CR, Butters MA, Flint AJ, Gallagher D, et al. Sex modifies the associations of APOE ɛ4 with neuropsychiatric symptom burden in both at-risk and clinical cohorts of Alzheimer’s disease. J Alzheimers Dis. 2022;90(4):1571–88.
pubmed: 36314203
doi: 10.3233/JAD-220586
Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. JNP. 2000;12(2):233–9.
doi: 10.1176/jnp.12.2.233